EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas

Ryan A Denu, Anand K Singh, Yingda Jiang, Zhao Zheng, Davis R Ingram, Khalida M Wani, Rossana Lazcano, Madison P Ginn, Kumaren Anand, Bishal K Singh, Jackson C Ballard, Veena Kochat und 22 weitere

Journal of Clinical Investigation · 10.11.2026

DOI: 10.1172/jci201343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 10.11.2026. Verfasst von Ryan A Denu und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conquer Cancer Foundation, National Institutes of Health, QuadW Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ATRX is one of the most frequently altered genes in sarcoma and encodes an ATP-dependent chromatin remodeler implicated in maintaining heterochromatin. However, ATRX alterations have not been leveraged for sarcoma treatment. We observed loss of ATRX protein in 14% of soft tissue leiomyosarcoma (STLMS, n =127), 53% of uterine leiomyosarcoma (ULMS, n = 95), 37% of undifferentiated pleomorphic sarcoma (UPS, n = 82), and 8% of dedifferentiated liposarcoma (DDLPS, n = 84). ATRX loss was associated with significantly worse outcomes in ULMS, UPS, and DDLPS. ATRX knockout in sarcoma cells increased proliferation in cooperation with TP53 deletion, chromatin remodeling, and enrichment of PRDM4 and NFIX transcription factor motifs. PRDM4 and NFIX knockdown in ATRX -mutant sarcoma lines resulted in reduced proliferation and invasion, suggesting an epistatic relationship. Consistent with the known and re-demonstrated functional relationship between PRMD4 and YAP1, ATRX loss activated YAP1-TEAD signaling, and ATRX -deficient cells and sarcoma xenografts were more sensitive to the TEAD inhibitors VT103 and IAG933. Overall, our results identify ATRX loss as a prognostic factor of worse outcomes, implicate the ATRX-PRDM4-YAP1-TEAD axis as an underlying mechanism, and suggest use of TEAD inhibition as a potential therapeutic strategy for ATRX -deficient sarcomas.

Schlagwörter

Stichwörter der Autor:innen

CancerCell biologyEpigeneticsGenetic instabilityGeneticsOncology

Autor:innen und Institutionen

  • Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America.
  • Department of Genomic Medicine, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, United States of America.
  • Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, United States of America.
  • University of Texas Health Sciences Center at Houston, Houston, United States of America.
  • Rice University, Houston, United States of America.
  • Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, United States of America.

Förderung

  • Conquer Cancer Foundation
  • National Institutes of Health
  • QuadW Foundation
  • National Leiomyosarcoma Foundation
  • Jay Vernon Jackson Liposarcoma Fund

Zitieren

APA

Denu, R. A., Singh, A. K., Jiang, Y., Zheng, Z., Ingram, D. R., Wani, K. M., Lazcano, R., Ginn, M. P., Anand, K., Singh, B. K., Ballard, J. C., Kochat, V., Chatterjee, B., Padron, W., Landers, S. M., Bhalla, A. D., Multani, A. S., Dharmaiah, S., Malgulwar, P. B., …, & Rai, K. (2026). ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas. Journal of Clinical Investigation. https://doi.org/10.1172/jci201343

Vancouver

Denu RA, Singh AK, Jiang Y, Zheng Z, Ingram DR, Wani KM, et al. ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas. Journal of Clinical Investigation. 2026. doi:10.1172/jci201343

BibTeX
@article{Denu2026,
  author = {Denu, Ryan A and Singh, Anand K and Jiang, Yingda and Zheng, Zhao and Ingram, Davis R and Wani, Khalida M and Lazcano, Rossana and Ginn, Madison P and Anand, Kumaren and Singh, Bishal K and Ballard, Jackson C and Kochat, Veena and Chatterjee, Biji and Padron, William and Landers, Sharon M and Bhalla, Angela D and Multani, Asha S and Dharmaiah, Sharvari and Malgulwar, Prit Benny and Cai, Yiming and Yao, Jun and Lin, Heather and Huse, Jason T and Ying, Haoqiang and Keung, Emily Z and Wang, Wei-Lien and Conley, Anthony P and Patel, Shreyaskumar and Somaiah, Neeta and Farooqi, Ahsan S and Lazar, Alexander J and Nassif Haddad, Elise F and Torres, Keila E and Rai, Kunal},
  title = {ATRX loss predicts poor outcomes and sensitizes to TEAD inhibition in soft tissue sarcomas},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci201343}
}
Kostenlos starten →